» Articles » PMID: 34681913

Functional Depletion of HSP72 by SiRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Oct 23
PMID 34681913
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Histone deacetylase inhibitors (HDACis) are one of the therapeutic options for cutaneous T-cell lymphoma (CTCL), but they have limited effects. We previously demonstrated that HSP72 overexpression is associated with chemoresistance to HDACis in lymphoma cells. The purpose of this study was to investigate whether the functional depletion of HSP72 enhances the effect of the HDACi vorinostat. First, we established a stable HSP72-knockdown CTCL cell line and confirmed the influence of HSP72 reduction on the antitumor effects of vorinostat. Next, we studied the effect of quercetin, an inhibitor of HSP72, on the antineoplastic effects of vorinostat. In five CTCL cell lines examined, HSP72 expression was highest in Hut78 cells, and HSP72 knockdown enhanced vorinostat-induced apoptosis in these cells. Low-dose quercetin reduced HSP72 expression, increased HDAC activity, and enhanced vorinostat-induced suppression of Hut78 cell proliferation. A single low dose of quercetin induced G2 arrest and only slightly increased the sub-G1 cell fraction. Quercetin also significantly enhanced vorinostat-induced apoptosis, caspase-3, caspase-8, and caspase-9 activity, and the loss of mitochondrial membrane potential. HSP72 knockdown enhanced vorinostat-induced apoptosis in an HSP72-overexpressing CTCL cell line, and thus, quercetin may be a suitable candidate for combination therapy with vorinostat in clinical settings.

Citing Articles

Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies.

Zuo W, Pang Q, Zhu X, Yang Q, Zhao Q, He G J Hematol Oncol. 2024; 17(1):81.

PMID: 39232809 PMC: 11375894. DOI: 10.1186/s13045-024-01601-1.


Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression.

Wang D, Zhang Y, Li Q, Li Y, Li W, Zhang A Genes Dis. 2024; 11(5):101020.

PMID: 38988323 PMC: 11233905. DOI: 10.1016/j.gendis.2023.04.040.


Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review).

Zhang Y, Chu J, Hou Q, Qian S, Wang Z, Yang Q Int J Oncol. 2024; 64(6).

PMID: 38757347 PMC: 11095602. DOI: 10.3892/ijo.2024.5653.


Flavonoids Regulate Redox-Responsive Transcription Factors in Glioblastoma and Microglia.

Joma N, Zhang I, Righetto G, McKay L, Gran E, Kakkar A Cells. 2023; 12(24).

PMID: 38132142 PMC: 10871111. DOI: 10.3390/cells12242821.


Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.

Wahi A, Jain P, Sinhari A, Jadhav H Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(2):675-702.

PMID: 37615708 DOI: 10.1007/s00210-023-02674-4.


References
1.
Fujii K . New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Front Oncol. 2018; 8:198. PMC: 5994426. DOI: 10.3389/fonc.2018.00198. View

2.
Sanli H, Akay B, Anadolu R, Ozcan M, Saral S, Akyol A . The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. J Drugs Dermatol. 2011; 10(4):403-8. View

3.
Jia J, Chen J . Histone hyperacetylation is involved in the quercetin-induced human leukemia cell death. Pharmazie. 2008; 63(5):379-83. View

4.
Dummer R, Beyer M, Hymes K, Epping M, Bernards R, Steinhoff M . Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012; 53(8):1501-8. DOI: 10.3109/10428194.2012.656625. View

5.
Uehara J, Honma M, Ohishi Y, Ishida-Yamamoto A . Successful combination therapy of low-dose vorinostat, etretinate and narrowband ultraviolet B irradiation for Sézary syndrome. J Dermatol. 2016; 44(3):e30-e31. DOI: 10.1111/1346-8138.13531. View